hero image

Biogen to Report First Quarter 2015 Financial Results on April 24, 2015

April 1, 2015 News Release

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Inc. (NASDAQ:BIIB) today announced it will report first quarter 2015 financial results on Friday, April 24, 2015, before the financial markets open.

Following the release of the financials, the Company will host a live webcast where Biogen management will discuss the financial results, at 8:00 am ET. To access the live webcast, please go to the investor relations section of Biogen’s website at www.biogen.com. Following the live webcast, an archived version of the call will be available at the same URL, for one month.

About Biogen

Through cutting-edge science and medicine, Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For product labeling, press releases and additional information about the company, please visit www.biogen.com.

Contact:

Biogen
Karen Jewell, 781-464-2442
Investor Relations

thumb
January 29, 2023
Lecanemab Receives Priority Review Status in Japan

TOKYO and CAMBRIDGE, Mass., Jan. 29, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that an application for

thumb
January 26, 2023
Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency

TOKYO and CAMBRIDGE, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the European Medicines